ATE458490T1 - Neues verfahren und neue zusammensetzung zur hemmung der angiogenese und des tumorwachstums unter verwendung von verbindungen auf basis einer sequenz in mmp-2 - Google Patents

Neues verfahren und neue zusammensetzung zur hemmung der angiogenese und des tumorwachstums unter verwendung von verbindungen auf basis einer sequenz in mmp-2

Info

Publication number
ATE458490T1
ATE458490T1 AT02731973T AT02731973T ATE458490T1 AT E458490 T1 ATE458490 T1 AT E458490T1 AT 02731973 T AT02731973 T AT 02731973T AT 02731973 T AT02731973 T AT 02731973T AT E458490 T1 ATE458490 T1 AT E458490T1
Authority
AT
Austria
Prior art keywords
mmp
tumor growth
inhibiting angiogenesis
sequence
amino acid
Prior art date
Application number
AT02731973T
Other languages
English (en)
Inventor
Peter C Brooks
Dorothy Rodriguez
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE458490T1 publication Critical patent/ATE458490T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02731973T 2001-06-01 2002-05-31 Neues verfahren und neue zusammensetzung zur hemmung der angiogenese und des tumorwachstums unter verwendung von verbindungen auf basis einer sequenz in mmp-2 ATE458490T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/872,165 US7019108B2 (en) 2001-06-01 2001-06-01 Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
PCT/US2002/017009 WO2002098351A2 (en) 2001-06-01 2002-05-31 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2

Publications (1)

Publication Number Publication Date
ATE458490T1 true ATE458490T1 (de) 2010-03-15

Family

ID=25358978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731973T ATE458490T1 (de) 2001-06-01 2002-05-31 Neues verfahren und neue zusammensetzung zur hemmung der angiogenese und des tumorwachstums unter verwendung von verbindungen auf basis einer sequenz in mmp-2

Country Status (10)

Country Link
US (1) US7019108B2 (de)
EP (1) EP1572066B1 (de)
JP (1) JP2005517628A (de)
CN (1) CN1636059A (de)
AT (1) ATE458490T1 (de)
AU (1) AU2002303908B2 (de)
CA (1) CA2448828A1 (de)
DE (1) DE60235505D1 (de)
MX (1) MXPA03010968A (de)
WO (1) WO2002098351A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
FR2856598B1 (fr) * 2003-06-25 2005-10-28 Inst Nat Sante Rech Med Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
EP1928497A2 (de) * 2005-08-24 2008-06-11 Cell-Matrix, Inc. Kombinationstherapien zur hemmung von interaktionen zwischen integrin und extrazellulärer matrix
AU2007258262A1 (en) * 2006-06-14 2007-12-21 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof
US8481477B2 (en) 2010-01-12 2013-07-09 New York University Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors
KR102035407B1 (ko) * 2015-04-27 2019-10-22 맥케이 메모리얼 호스피탈 자가 면역 및 염증성 질환의 치료 및/또는 예방을 위한 짧은 합성 펩타이드

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0907661A4 (de) * 1996-05-31 2000-07-26 Scripps Research Inst Methoden und zusammensetzungen für die hemmung von alpha-v-beta5 vermittelter angiogenese.
AU738782B2 (en) * 1996-05-31 2001-09-27 Scripps Research Institute, The Methods and compositions useful for inhibition of alphavbeta5 mediated angiogenesis
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition

Also Published As

Publication number Publication date
US20020182215A1 (en) 2002-12-05
EP1572066B1 (de) 2010-02-24
DE60235505D1 (de) 2010-04-08
AU2002303908B2 (en) 2008-02-21
JP2005517628A (ja) 2005-06-16
WO2002098351A8 (en) 2006-05-11
US7019108B2 (en) 2006-03-28
EP1572066A2 (de) 2005-09-14
EP1572066A4 (de) 2007-09-19
WO2002098351A2 (en) 2002-12-12
MXPA03010968A (es) 2004-10-28
CA2448828A1 (en) 2002-12-12
CN1636059A (zh) 2005-07-06

Similar Documents

Publication Publication Date Title
ATE270280T1 (de) Substituierte dipeptide zur förderung der sekretion von wachstumshormon
EP1548032A4 (de) Kdr-peptide und diese enthaltende impfstoffe
MXPA03000627A (es) Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
FI20050243A7 (fi) Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinipigmenttien valmistamiseksi
BR0211199A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
ATE317916T1 (de) Verfahren zur identifizierung von adeno- assoziiertem virus (aav) sequenzen sowie kit zur ausführung der methode
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE273364T1 (de) Zusammensetzungen zur stabilisierung von sauerstoffempfindlichen verbindungen
ATE458490T1 (de) Neues verfahren und neue zusammensetzung zur hemmung der angiogenese und des tumorwachstums unter verwendung von verbindungen auf basis einer sequenz in mmp-2
DE602004027767D1 (de) Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
ATE423785T1 (de) Verfahren und zusammensetzungen zur identifikation und charakterisierung von hepatitis c
IL173969A0 (en) Use of peptides derived from the a alpha or b beta chain of human of human fibrinogen for the treatment of shock
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
DE60326128D1 (de) Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen
EP1666880A4 (de) Screening-verfahren
DE60306636D1 (de) Wachstumhormonsekretionsförderer
DE60323222D1 (de) Verfahren und zusamensetzungen zum abtöten von sporen
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
DE602006017806D1 (de) Behandlung von neurodegeneration
DE50210473D1 (de) Phosphinat-peptidanaloga als inhibitoren der procollagen-c-proteinase (pcp) zur behandlung von fibrotischen erkrankungen
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
ATE529437T1 (de) Verfahren zur sauerstoff-regulierten produktion von recombinanter staphylokinase
DK1794294T3 (da) Rekombinant carboxypeptidase B

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties